US FDA approved Fulphila (pegfilgrastim-jmdb) – a biosimilar to Neulasta for reducing the chances of infection in patients with non-myeloid (non-bone marrow) cancer during chemotherapy. It is the first pegfilgrastim biosimilar that is approved by the US FDA.
This disease is not new in India but has revisited for the third time after previously outbreaking in the two districts of West Bengal – Siliguri and Nadia in 2001 and 2007 respectively. High fatality rate (about 70 percent) and easy person-to-person transmission of the disease had already been established during its previous encounters but still, there is no vaccine for the prevention or cure of the disease and only supportive treatment is given for the disease-related complications including neurological and respiratory complications.
Indian Institute of Technology Roorkee (IIT Roorkee) scientists have developed an improved orthopedic implant technology for sustained drug release. Currently, the technology is with the company, Biotech Consortium India Limited (BCIL) for transfer, for the commercialization of the technology.
First drug treatment- Jynarque (tolvaptan) to slow down the decline in kidney function in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) received USFDA approval. The drug is developed by Japanese biopharma, Otsuka Pharma.